v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue:        
Research and development $ 95,833 $ 33,333 $ 95,833
Costs and expenses:        
Research and development 4,621,255 3,336,225 10,343,451 10,833,345
General and administrative 2,256,689 2,364,214 7,710,625 6,980,155
Total costs and expenses 6,877,944 5,700,439 18,054,076 17,813,500
Loss from operations (6,877,944) (5,604,606) (18,020,743) (17,717,667)
Sale of New Jersey net operating loss & tax credits 1,328,470 1,073,289
Other income, net 41,394 155,093 108,298 538,420
Net loss (6,836,550) (5,449,513) (16,583,975) (16,105,958)
Preferred stock series B accumulated dividends (227,600) (395,799) (575,392)
Net loss attributable to common shareholders $ (6,836,550) $ (5,677,113) $ (16,979,774) $ (16,681,350)
Net loss available for common shareholders per share - basic and diluted $ (0.03) $ (0.03) $ (0.08) $ (0.09)
Weighted average common shares outstanding – basic and diluted 215,179,949 198,909,016 208,130,431 196,070,952
Other comprehensive (loss)/income, net of tax        
Net unrealized (loss)/gain on securities available-for-sale $ (52,837) $ (114,159) $ (229,766) $ 367,144
Reclassifications to net loss (2,719)
Other comprehensive (loss)/income, net of tax (52,837) (114,159) (229,766) 364,425
Comprehensive loss attributable to shareholders $ (6,889,387) $ (5,563,672) $ (16,813,741) $ (15,741,533)

Source